Skip to main content
Premium Trial:

Request an Annual Quote

FlowMetric, BurstIQ Collaborate on Blockchain Technology for Personalized Medicine

NEW YORK (360Dx) – FlowMetric Life Sciences said today that it has entered a personalized medicine partnership with healthcare blockchain data company BurstIQ.

Coupling its service with the BurstIQ blockchain platform will provide consumers with data security and the ability to govern how their personal information is shared, utilized, and monetized, FlowMetric said, adding initial applications will focus on FlowMetric's direct-to-consumer line of health-and-wellness testing products.

Frank Ricotta, CEO of BurstIQ, said in a statement that people who have completed a FlowMetric personalized medicine test "will be able to access and control their test results, combine it with other health data, and gain real value from that data through marketplaces of products, services, and research opportunities tailored just for them."

FlowMetric said that its suite of personalized medicine products will initially include chromosomal age tests, cellular toxicity analysis, and oxidative stress and inflammation monitoring. The products will employ BurstIQ’s digital token-based monetization platform offered through its healthcare marketplace.

In the future, FlowMetric will offer to its pharma customers BurstIQ’s proprietary blockchain platform and advanced intelligence layer. That is expected to enable a secure and auditable chain of custody tracking for clinical sample analysis and allow secure data exchange between FlowMetric and its enterprise customers, FlowMetric said.

FlowMetric's CEO Ren Capocasale said that the BurstIQ platform "opens new distribution and partnership channels" that will accelerate his firm's growth.